Entering text into the input field will update the search result below

CEL-SCI dips on $22.62M capital raise

  • A Phase 3 cancer immunotherapy company, CEL-SCI (NYSE:CVM), enters into an underwriting agreement with Kingswood Capital Markets to purchase 1M shares at a price to the public of $22.62 per share.
  • The price represents a 5% discount to the company’s June 8, 2021

Recommended For You

About CVM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CVM--
CEL-SCI Corporation